



IPW

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Carl G. Hellerqvist et al.)
)
Serial No. **10/823,506**)
)
Filed: **April 12, 2004**)
)
For: **GBS Toxin Receptor**)

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO-1449, "Information Disclosure Statement by Applicant" is made pursuant to 37 C.F.R. §§ 1.97 and 1.98. A copy of each cited item is enclosed unless stated otherwise hereinbelow.

Pursuant to 37 C.F.R. §1.98(d), inasmuch as this application relies on prior application Serial No. 09/359,167 filed July 21, 1999, no copy of any patent, publication or other information previously cited by or submitted to the Office in such prior application is being provided herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on October 27, 2004.

Elena S. Polovnikova

Elena S. Polovnikova - Reg. No. 52,130

The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Elena S. Polovnikova".

Elena S. Polovnikova, Ph.D.
Patent Agent
Reg. No. 52,130

KILPATRICK STOCKTON LLP
1100 Peachtree Street; Suite 2800
Atlanta, Georgia 22100-0202
Our Docket: 49530-299673 (22100-0202)

Under the Paperwork Reduction Act of 1996 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 3 |
|-------|---|----|---|

Complete if Known

| | |
|-------------------------------|----------------------------------|
| Application Number | 10/823,506 |
| Filing Date | April 12, 2004 |
| First Named Inventor | Carl G. Hellerqvist |
| Group Art Unit | Not yet assigned |
| Examiner Name | Not yet assigned |
| Attorney Docket Number | 22100-0202 (49530-299673) |

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | |
|---|--|--------------------------|------------------------|---------------------------|
| Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | |
| | | Application Number | 10/823,506 | |
| | | Filing Date | April 12, 2004 | |
| | | First Named Inventor | Carl G. Hellerqvist | |
| | | Group Art Unit | Not yet assigned | |
| | | Examiner Name | Not yet assigned | |
| Sheet | | of | Attorney Docket Number | 22100-0202 (49530-299673) |

| OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | 13 | DEVORE <i>et al.</i> , "Phase I Study of the Antineovascularization Drug CM101," <i>Clinical Cancer Research</i> , Vol. 3, pp. 365-372 (1997) | |
| | 14 | FU, <i>et al.</i> , "Expressional Cloning of CM101 Receptor Gene from Mammalian Cells," <i>Proceedings of the American Association of Cancer Research</i> , Abstract No. 3677, Vol. 40, p. 557 (1999) | |
| | 15 | GEARING, <i>et al.</i> , "Expression Cloning of a Receptor for Human Granulocyte-Macrophage Colony-Stimulating Factor," <i>The EMBO Journal</i> , Vol. 8, No. 12, pp. 3667-3676 (1989) | |
| | 16 | HELLERQVIST <i>et al.</i> , "Anti-Tumor Effects of GBS Toxin are Caused by Induction of a Targeted Inflammatory Reaction," <i>Angiogenesis: Molecular Biology, Clinical Aspects</i> , Edited by Maragoudakis <i>et al.</i> , Plenum Press, New York, pp. 265-269 (1994) | |
| | 17 | HELLERQVIST <i>et al.</i> , "Antitumor Effects of GBS Toxin: A Polysaccharide Exotoxin From Group B β -Hemolytic Streptococcus," <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 120, pp. 63-70 (1993) | |
| | 18 | HELLERQVIST <i>et al.</i> , "Molecular Basis for Group B β -Hemolytic Streptococcal Disease," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 84, pp.51-55 (1987) | |
| | 19 | HELLERQVIST <i>et al.</i> , "Preliminary Results of a Phase I Trial of CM101 in Cancer Patients," <i>J. Cellular Biochemistry</i> , Suppl. 19B, p. 26 (1995) | |
| | 20 | HELLERQVIST <i>et al.</i> , "Studies on Group B β -Hemolytic Streptococcus. I. Isolation and Partial Characterization of an Extracellular Toxin," <i>Pediatr. Res.</i> , Vol. 15, pp. 892-898 (1981) | |
| | 21 | HILLIER, <i>et al.</i> , "zr59d01.rl Soares NhHMPu S1 Homo sapiens cDNA clone 667681 5' Similar to Tr:G507415 G507415 Brain Specific Na ⁺ -Dependent Inorganic Phosphate Cotransporter," Database EMBL - EMBEST20 'Online!', Entry HS1173506, Acc. No. AA258513 (March 19, 1997) | |
| | 22 | KOVACS <i>et al.</i> , "Fibrogenic Cytokines and Connective Tissue Production," <i>The FASEB Journal</i> , Vol. 8, pp. 854-861 (1994) | |
| | 23 | NORRBY, "Angiogenesis: New Aspects Relating to Its Initiation and Control," <i>APMIS</i> , Vol. 105, pp. 417-437 (1997) | |
| | 24 | POLVERINI, "The Pathophysiology of Angiogenesis," <i>Crit. Rev. Oral. Biol. Med.</i> , Vol. 6, No. 3, pp.230-247 (1995) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|---|--|--------------------------|---------------------|------------------------|---------------------------|
| Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/823,506 | | |
| | | Filing Date | April 12, 2004 | | |
| | | First Named Inventor | Carl G. Hellerqvist | | |
| | | Group Art Unit | Not yet assigned | | |
| | | Examiner Name | Not yet assigned | | |
| Sheet | | of | | Attorney Docket Number | 22100-0202 (49530-299673) |

| OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | 25 | QUINN, <i>et al.</i> , "CM101, A Polysaccharide Antitumor Agent, Does Not Inhibit Wound Healing in Murine Models," <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 121, pp.253-256 (1995) | |
| | 26 | THURMAN, <i>et al.</i> , "Actue Inflammatory Changes in Subcutaneous Microtumors in the Ears of Mice Induced by Intravenous CM101 (GBS Toxin)," <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 122, pp. 549-553 (1996) | |
| | 27 | WAMIL, <i>et al.</i> , "Soluble E-Selectin in Cancer Patients as a Maker of the Therapeutic Efficacy of CM101, a Tumor-Inhibiting Anti-Neovascularization Agent, Elevated in Phase I Clinical Trail," <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 123, pp. 173-179 (1997) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.